Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE DES 3 CITES : revenue, balance sheet and financial ratios

SELARL PHARMACIE DES 3 CITES is a French company founded 8 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in SAINT-DENIS (93200), this company of category PME shows in 2020 a net income positive of 201 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE DES 3 CITES (SIREN 839048626)
Indicator 2020
Revenue N/C
Net income 201 226 €
EBITDA N/C
Net margin N/C

Revenue and income statement

In 2020, SELARL PHARMACIE DES 3 CITES generates positive net income of 201 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2020) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

201 226 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 390%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 15%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2020) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

390.057%

Financial autonomy (2020) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

15.204%

Asset age ratio (2020) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

76.4%

Solvency indicators evolution
SELARL PHARMACIE DES 3 CITES

Sector positioning

Debt ratio
390.06 2020
2020
Q1: 33.2
Med: 96.78
Q3: 238.43
Average

In 2020, the debt ratio of SELARL PHARMACIE DES 3 CITES (390.06) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
15.2% 2020
2020
Q1: 23.59%
Med: 41.65%
Q3: 61.95%
Watch

In 2020, the financial autonomy of SELARL PHARMACIE DES 3 CITES (15.2%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 195.18. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2020) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

195.176

Liquidity indicators evolution
SELARL PHARMACIE DES 3 CITES

Sector positioning

Liquidity ratio
195.18 2020
2020
Q1: 133.12
Med: 181.89
Q3: 251.9
Good

In 2020, the liquidity ratio of SELARL PHARMACIE DES 3 CITES (195.18) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 220 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 1046 days. Excellent situation: suppliers finance 826 days of the operating cycle (retail model).

Operating WCR (2020) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2020) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

220 j

Supplier credit (2020) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

1046 j

Inventory turnover (2020) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE DES 3 CITES

Positioning of SELARL PHARMACIE DES 3 CITES in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 180 transactions of similar company sales in 2020, the value of SELARL PHARMACIE DES 3 CITES is estimated at 2 843 858 € (range 1 896 244€ - 3 837 132€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2020
180 transactions
1896k€ 2843k€ 3837k€
2 843 858 € Range: 1 896 244€ - 3 837 132€
NAF 5 année 2020

Valuation method used

Net Income Multiple
201 226 € × 14.1x = 2 843 858 €
Range: 1 896 245€ - 3 837 133€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 180 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE DES 3 CITES with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE DES 3 CITES

What is the revenue of SELARL PHARMACIE DES 3 CITES ?

The revenue of SELARL PHARMACIE DES 3 CITES is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE DES 3 CITES profitable?

Yes, SELARL PHARMACIE DES 3 CITES generated a net profit of 201 k€ in 2020.

Where is the headquarters of SELARL PHARMACIE DES 3 CITES ?

The headquarters of SELARL PHARMACIE DES 3 CITES is located in SAINT-DENIS (93200), in the department Seine-Saint-Denis.

Where to find the tax return of SELARL PHARMACIE DES 3 CITES ?

The tax return of SELARL PHARMACIE DES 3 CITES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE DES 3 CITES operate?

SELARL PHARMACIE DES 3 CITES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.